Randomized Treatment Interruption of Natalizumab
Randomized Treatment Interruption of Natalizumab
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
Compared with
- Glatiramer acetate
Unknown
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Methylprednisolone
Glucocorticoid receptor agonist
What it measured
Main measures
Natalizumab concentration, immune function, pharmacodynamics, disease activity
Loading reviews and guidelines…
Related trials
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- A Study Utilising Data From European Union (EU) National Multiple Scle
Running, not recruiting
Still running
- A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated M
Stopped early
Stopped
- A Study to Investigate the Radiological Onset of Action After Treatmen
Phase 4 · Stopped early
Stopped
- The 'Wearing Off' Effect of DMT
Completed
No results found
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacody
Phase 3 · Stopped early
Stopped: not working
History
- In scope changed from true to false
Started
Feb 2010
Assembled by software from public sources.